Evaluation of phospholipid transfer protein as a therapeutic target

Future Lipidology

Volumn 3, Issue 3, 2008, Pages 327-335

  Vergeer, Menno ^a   Dallinga Thie, Geesje M ^a   Dullaart, Robin P F ^b   van Tol, Arie ^b,c  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Atherosclerosis; Diabetes; Lipoprotein metabolism; Obesity; Phospholipid transfer protein; PLTP

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PHOSPHOLIPID TRANSFER PROTEIN;

ATHEROSCLEROSIS; DIABETES MELLITUS; DRUG TARGETING; HUMAN; LIPOPROTEIN METABOLISM; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALIA;

EID: 47749111644     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460875.3.3.327     Document Type: Review

References (73)

1. Chumlea WC, Guo SS, Zeller CM, Reo NV, Siervogel RM: Total body water data for white adults 18 to 64 years of age: the Fels Longitudinal Study. Kidney Int. 56(1), 244-252 (1999).
2. Van Tol A: Phospholipid transfer protein. Curr. Opin. Lipidol. 13(2), 135-139 (2002).
3. Day JR, Albers JJ, Lofton-Day CE et al.: Complete cDNA encoding human phospholipid transfer protein from human endothelial cells. J. Biol. Chem. 269(12), 9388-9391 (1994).
4. Whitmore TE, Day JR, Albers JJ: Localization of the human phospholipid transfer protein gene to chromosome 20q12-q13.1. Genomics 28(3), 599-600 (1995).
5. Dusserre E, Moulin P, Vidal H: Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim. Biophys. Acta 1500(1), 88-96 (2000).
6. Albers JJ, Cheung MC: Emerging roles for phospholipid transfer protein in lipid and lipoprotein metabolism. Curr. Opin. Lipidol. 15(3), 255-260 (2004).
7. Cheung MC, Albers JJ: Active plasma phospholipid transfer protein is associated with ApoA-I- but not ApoE-containing lipoproteins. J. Lipid Res. 47(6), 1315-1321 (2006).
8. Van Haperen R, van Tol A, van Gent T et al.: Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein. J. Biol. Chem. 277(50), 48938-48943 (2002).
9. Lie J, de Crom R, van Gent T et al.: Elevation of plasma phospholipid transfer protein in transgenic mice increases VLDL secretion. J. Lipid Res. 43(11), 1875-1880 (2002).
10. Lie J, de Crom R, van Gent T et al.: Elevation of plasma phospholipid transfer protein increases the risk of atherosclerosis despite lower apolipoprotein B-containing lipoproteins. J. Lipid Res. 45(5), 805-811 (2004).
11. Yang XP, Yan D, Qiao C et al.: Increased atherosclerotic lesions in ApoE mice with plasma phospholipid transfer protein overexpression. Arterioscler. Thromb. Vasc. Biol. 23(9), 1601-1607 (2003).
12. Jiang XC, Qin S, Qiao C et al.: Apolipoprotein B secretion and atherosclerosis are decreased in mice with phospholipid-transfer protein deficiency. Nat. Med. 7(7), 847-852 (2001).
13. Settasatian N, Duong M, Curtiss LK et al.: The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J. Biol. Chem. 276(29), 26898-26905 (2001).
14. Brooks-Wilson A, Marcil M, Clee SM et al.: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22(4), 336-345 (1999).
15. Curtiss LK, Valenta DT, Hime NJ, Rye KA: What is so special about apolipoproteln AI in reverse cholesterol transport? Arterioscler. Thromb. Vasc. Biol. 26(1), 12-19 (2006).
16. Wolfbauer G, Albers JJ, Oram JF: Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim. Biophys. Acta 1439(1), 65-76 (1999).
17. Oram JF, Wolfbauer G, Vaughan AM, Tang C, Albers JJ: Phospholipid transfer protein interacts with and stabilizes ATP-binding cassette transporter A1 and enhances cholesterol efflux from cells. J. Biol. Chem. 278(52), 52379-52385 (2003).
18. Desrumaux CM, Mak PA, Boisvert WA et al.: Phospholipid transfer protein is present in human atherosclerotic lesions and is expressed by macrophages; and foam cells. J. Lipid Res. 44(8). 1453-1461 (2003).
19. O'Brien KD, Vuletic S, McDonald TO et al.: Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 108(3), 270-274 (2003).
20. Ogier N, Klein A, Deckert V et al.: Cholesterol accumulation is increased in macrophages of phospholipid transfer protein-deficient mice: normalization by dietary α-tocopherol supplementation. Arterioscler. Thromb. Vasc. Biol. 27(11), 2407-2412 (2007).
21. Setala NL, Holopainen JM, Metso J et al.: Interfacial and lipid transfer properties of human phospholipid transfer protein: implications for the transfer mechanism of phospholipids. Biochemistry 46(5), 1312-1319 (2007).
22. Jiang XC, Li Z, Liu R et al.: Phospholipid transfer protein deficiency impairs apolipoprotein-B secretion from hepatocytes by stimulating a proteolytic pathway through a relative deficiency of vitamin E and an increase in intracellular oxidants. J. Biol. Chem. 280(18), 18336-18340 (2005).
23. Liu R, Iqbal J, Yeang C, Wang DQH, Hussain MM, Jiang XC: Phospholipid transfer protein deficient mice absorb less cholesterol. Arterioscler. Thromb. Vasc. Biol. 27(9), 2014-2021 (2007).
24. Jiang XC, Tall AR, Qin S et al.: Phospholipid transfer protein deficiency protects circulating lipoproteins from oxidation due to the enhanced accumulation of vitamin E. J. Biol. Chem. 277(35), 31850-31856 (2002).
25. Schlitt A, Liu J, Yan D, Mondragon-Escorpizo M, Norin AJ, Jiang XC: Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochim. Biophys. Acta 1733(2-3), 187-191 (2005).
26. Shelly L, Royer L, Sand T, Jensen H, Luo Y: Phospholipid transfer protein deficiency ameliorates diet-induced hypercholesterolemia and inflammation in mice. J. Lipid Res. 49, 773-781 (2008).
27. Vikstedt R, Ye D, Metso J et al.: Macrophage phospholipid transfer protein contributes significantly to total plasma phospholipid transfer activity and its deficiency leads to diminished atherosclerotic lesion development. Arterioscler. Thromb. Vasc. Biol. 27(3), 578-586 (2007).
28. Van Haperen R, Samyn H, Moerland M et al.: Elevated macrophage expression of phospholipid transfer protein causes atherosclerosis (Abstract no. 1199). Circulation 114(Suppl. II-225) (2006).
29. Valenta DT, Ogier N, Bradshaw G et al.: Atheroprotective potential of macrophage-derived phospholipid transfer protein in low-density lipoprotein receptor-deficient mice is overcome by apolipoprotein AI overexpression. Arterioscler. Thromb. Vasc. Biol. 26(7), 1572-1578 (2006).
30. Valenta DT, Bulgrien JJ, Bonnet DJ, Curtiss LK: Macrophage PLTP is atheroprotective in LDLr-deficient mice with systemic PLTP deficiency. J. Lipid Res. 49(1), 24-32 (2008).
31. Liu R, Hojjati MR, Devlin CM, Hansen IH, Jiang XC: Macrophage phospholipid transfer protein deficiency and ApoE secretion: impact on mouse plasma cholesterol levels and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(1), 190-196 (2007).
32. Siggins S, Karkkainen M, Tenhunen J et al.: Quantitation of the active and low-active forms of human plasma phospholipid transfer protein by ELISA. J. Lipid Res. 45(2), 387-395 (2004).
33. Murdoch SJ, Wolfbauer G, Kennedy H, Marcovina SM, Carr MC, Albers JJ: Differences in reactivity of antibodies to active versus inactive PLTP significantly impacts PLTP measurement. J. Lipid Res. 43(2), 281-289 (2002).
34. Desrumaux C, Athias A, Bessede G et al.: Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler. Thromb. Vasc. Biol. 19(2), 266-275 (1999).
35. Karkkainen M, Oka T, Olkkonen VM et al.: Isolation and partial characterization of the inactive and active forms of human plasma phosphollpid transfer protein (PLTP). J. Biol. Chem. 277(18), 15413-15418 (2002).
36. Oka T, Kujiraoka T, Ito M et al.: Measurement of human plasma phospholipid transfer protein by sandwich ELISA. Clin. Chem. 46(9), 1357-1364 (2000).
37. Schlitt A, Bickel C, Thumma P et al.: High plasma phospholipid transfer protein levels as a risk factor for coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 23(10), 1857-1862 (2003).
38. Ruhling K, Lang A, Richard F et al.: Net mass transfer of plasma cholesteryl esters and lipid transfer proteins in normolipidemic patients with peripheral vascular disease. Metabolism 48(11), 1361-1366 (1999).
39. Schgoer W, Mueller T, Jauhiainen M et al.: Low phospholipid transfer protein (PLTP) is a risk factor for peripheral atherosclerosis. Atherosclerosis 196(1), 219-226 (2008).
40. De Vries R, Dallinga-Thie GM, Smit A et al.: Elevated plasma phospholipid transfer protein activity is a determinant of carotid intima-media thickness in Type 2 diabetes mellitus. Diabetologia 49 (2), 398-404 (2006).
41. Dullaart RPF, Shater WJ, Dikkeschei LD, Hoogenberg K, Van Tol A: Effect of adiposity on plasma lipid transfer protein activities: a possible link between insulin resistance and high density lipoprotein metabolism. Eur. J. Clin. Invest. 24(3), 188-194 (1994).
42. Murdoch SJ, Carr MC, Hokanson JE, Brunzell JD, Albers JJ: PLTP activity in premenopausal women: relationship with lipoprotein lipase, HDL, LDL, body fat, and insulin resistance. J. Lipid Res. 41(2), 237-244 (2000).
43. Kaser S, Sandhofer A, Foger B et al.: Influence of obesity and insulin sensitivity on phospholipid transfer protein activity. Diabetologia 44(9), 1111-1117 (2001).
44. Cheung MC, Knopp RH, Retzlaff B, Kennedy H, Wolfbauer G, Albers JJ: Association of plasma phospholipid transfer protein activity with IDL and buoyant LDL: impact of gender and adiposity. Biochim. Biophys. Acta 1587(1), 53-59 (2002).
45. Dullaart RP, Groen AK, Dalinga-Thie GM, de Vries R, Sluiter WJ, van Tol A: Fibroblast cholesterol efflux to plasma from metabolic syndrome subjects is not defective despite low high-density lipoprotein cholesterol. Eur. J. Endocrinol. 158(1), 53-60 (2008).
46. Murdoch SJ, Kahn SE, Albers JJ, Brunzell JD, Purnell JQ: PLTP activity decreases with weight loss: changes in PLTP are associated with changes in subcutaneous fat and FFA but not IAF or insulin sensitivity. J. Lipid Res. 44(9), 1705-1712 (2003).
47. Dullaart RP, de Vries R, Dallinga-Thie GM, van Tol A, Sluiter WJ: Plasma cholesteryl ester transfer protein mass and phospholipid transfer protein activity are associated with leptin in Type 2 diabetes mellitus. Biochim. Biophys. Acta 1771(1), 113-118 (2007).
48. Ashrafi K, Chang FY, Watts JL et al.: Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 421(6920), 268-272 (2003).
49. Lee J, Reed DR, Li W et al.: Genome scan for human obesity and linkage to markers in 20q13. Am. J. Hum. Genet. 64(1), 196-209 (1999).
50. Bosse Y, Bouchard L, Despres JP, Bouchard C, Perusse L, Vohl MC: Haplotypes in the phospholipid transfer protein gene are associated with obesity-related phenotypes: the Quebec Family Study. Int. J. Obes. Relat. Metab. Disord. 29(11), 1338-1345 (2005).
51. Riemens SC, van Tol A, Sluiter WJ, Dullaart RPF: Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese Type II diabetic patients. Diabetologia 41(8), 929-934 (1998).
52. Riemens SC, van Tol A, Sluiter WJ, Dullaart RP: Plasma phospholipid transfer protein activity is lowered by 24-h insulin and acipimox administration: blunted response to insulin in Type 2 diabetic patients. Diabetes 48(8), 1631-1637 (1999).
53. Dullaart RP, de Vries R, Dallinga-Thie GM, Sluiter WJ, van Tol A: Phospholipid transfer protein activity is determined by Type 2 diabetes mellitus and metabolic syndrome, and is positively associated with serum transaminases. Clin. Endocrinol. (Oxf.) 68(3), 375-381 (2007).
54. Colhoun HM, Taskinen MR, Otvos JD, van den Berg P, O'Connor J, van Tol A: Relationship of phospholipid transfer protein activity to HDL and apolipoprotein B-containing lipoproteins in subjects with and without Type 1 diabetes. Diabetes 51(11), 3300-3305 (2002).
55. Colhoun HM, Scheek LM, Rubens MB et al.: Lipid transfer protein activities in Type 1 diabetic patients without renal failure and nondiabetic control subjects and their association with coronary artery calcification. Diabetes 50(3), 652-659 (2001).
56. De Vries R, Kerstens MN, Sluiter WJ, Groen AK, Van Tol A, Dullaart RPF: Cellular cholesterol efflux to plasma from moderately hypercholesterolaemic Type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 48(6), 1105-1113 (2005).
57. Kaser S, Foger B, Ebenbichler CF et al.: Influence of leptin and insulin on lipid transfer proteins in human hepatoma cell line, HepG2. Int. J. Obes. Relat. Metab. Disord. 25(11), 1633-1639 (2001).
58. Tu AY, Albers JJ: Glucose regulates the transcription of human genes relevant to HDL metabolism: responsive elements for peroxisome proliferator-activated receptor are involved in the regulation of phospholipid transfer protein. Diabetes 50(8), 1851-1856 (2001).
59. Riemens SC, Van Tol A, Sluiter WJ, Dullaart RPF: Acute and chronic effects of a 24-hour intravenous triglyceride emulsion challenge on plasma lecithin: cholesterol acyltransferase, phospholipid transfer protein, and cholesteryl ester transfer protein activities. J. Lipid Res. 40(8), 1459-1466 (1999).
60. Dallinga-Thie GM, van Tol A, Hattori H, Rensen PCN, Sijbrands EJG; for the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group: Plasma phospholipid transfer protein activity is decreased in Type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E? Diabetes 55(5), 1491-1496 (2006).
61. Siggins S, Jauhiainen M, Olkkonen VM, Tenhunen J, Ehnholm C: PLTP secreted by HepG2 cells resembles the high-activity PLTP form in human plasma. J. Lipid Res. 44(9), 1698-1704 (2003).
62. Janis MT, Metso J, Lankinen H et al.: Apolipoprotein E activates the low-activity form of human phospholipid transfer protein. Biochem. Biophys. Res. Commun. 331(1), 333-340 (2005).
63. Tan KC, Shiu SW, Wong Y, Wong WK, Tam S: Plasma apolipoprotein E concentration is an important determinant of phospholipid transfer protein activity in Type 2 diabetes mellitus. Diabetes Metab. Res. Rev. 22 (4), 307-312 (2006).
64. Vuletic S, Peskind ER, Marcovina SM et al.: Reduced CSF PLTP activity in Alzheimer's disease and other neurologic diseases; PLTP induces ApoE secretion in primary human astrocytes in vitro. J. Neurosci. Res. 80(3), 406-413 (2005).
65. Jonkers IJ, Smelt AH, Hattori H et al.: Decreased PLTP mass but elevated PLTP activity linked to insulin resistance In HTG: effects of bezafibrate therapy. J. Lipid Res. 44(8), 1462-1469 (2003).
66. Cao G, Beyer TP, Yang XP et al.: Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. 277(42), 39561-39565 (2002).
67. Steffensen KR, Gustafsson JA: Putative metabolic effects of the liver X receptor (LXR). Diabetes 53(90001), S36-S42 (2004).
68. Mak PA, Kast-Woelbern HR, Anisfeld AM, Edwards PA: Identification of PLTP as an LXR target gene and ApoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43(12), 2037-2041 (2002).
69. Schultz JR, Tu H, Luk A et al.: Role of LXRs in control of lipogenesis. Genes Dev. 14(22), 2831-2838 (2000).
70. Grefhorst A, Elzinga BM, Voshol PJ et al.: Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277(37), 34182-34190 (2002).
71. Tangirala RK, Bischoff ED, Joseph SB et al.: Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl Acad. Sci. USA 99(18), 11896-11901 (2002).
72. Cao, G, Liang Y, Broderick CL et al.: Antidiabetic action of a liver X receptor agonist mediated by inhibition of hepatic gluconeogenesis. J. Biol. Chem. 278(2), 1131-1136 (2003).
73. Commerford SR, Vargas L, Dorfman SE et al.: Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol. Endocrinol. 21(12), 3002-3012 (2007).